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Objective: Pancreatic enzyme replacement therapy (PERT) is critical for achieving
adequate nutrition in cystic ﬁbrosis (CF) patients with exocrine pancreatic insufﬁ-
ciency (EPI). This study assessed efﬁcacy and safety of a new formulation of Creon
24,000-unit capsules (study drug), in CF subjects with EPI.
Methods: This was a double-blind, randomized, placebo-controlled, two-period
(5 days each) cross-over study in patients with CF  12 years of age with EPI.
Patients were randomized to one of two sequences, study drug then placebo, or
placebo then study drug with a 3−14 days interval in-between on their usual PERT.
Dosing was targeted at 4000 lipase units/g fat intake. The primary outcome measure
was the coefﬁcient of fat absorption (CFA); secondary outcomes were coefﬁcient
of nitrogen absorption (CNA), symptoms, and safety parameters.
Results: Thirty-two subjects were randomized (16 per arm). CFA and CNA were
signiﬁcantly greater with study drug than placebo (LS means: CFA, 88.6% vs
49.6%; CNA, 85.1% vs 49.9%; p< 0.001 for both). Symptoms of EPI were im-
proved with study drug compared with placebo. Fewer treatment-emergent adverse
events (TEAEs) were reported by patients on study drug than placebo. One patient
discontinued due to an AE one day after last day of study drug.
Conclusion: Results of this study demonstrated Creon was effective in treating fat
maldigestion and malabsorption associated with EPI due to CF, and was safe and
well tolerated.
Supported by: Solvay Pharmaceuticals GmbH, Hannover, Germany.
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Objective: Pancreatic enzyme replacement therapy (PERT) is essential to maintain
adequate nutrition in patients with exocrine pancreatic insufﬁciency (EPI) due to
cystic ﬁbrosis (CF). Our objective was to report Solvay Pharmaceuticals’ worldwide
experience on the efﬁcacy and safety of CREON in children <7 years old with EPI
due to CF.
Methods: This was a pooled analysis of safety data of children <7 years old
with EPI due to CF from all multiple-dose studies of CREON enrolling patients
in this age group. Treatment-emergent adverse events (TEAEs) were coded using
MedDRA Version 8.1. Efﬁcacy data (coefﬁcient of fat absorption, CFA) for this
patient population were available from four studies.
Results: Regarding efﬁcacy in four studies providing CFA data, on-treatment
mean values ranged from 78% to 91%. The safety analysis included 91 children
<7 years old with a median age of 2.6 years (range, 1 month to 7 years). The
median daily lipase dose administered in U/kg/day was 5936 (0 to <4 years) and
5729 (4 to <7 years). In total, 56 children (61.5%) experienced a TEAE. Serious
TEAEs were reported in two children (bronchial obstruction and pseudomonal lung
infection); both were considered unrelated to study drug and both patients completed
the study. Ten children (11.0%) experienced TEAEs considered treatment related.
There were no deaths.
Conclusion: This analysis emphasizes that in children <7 years old with EPI due to
CF, CREON was well tolerated, with an AE proﬁle consistent with the underlying
disease for this age group, and was effective in treating maldigestion in this pediatric
population.
Supported by: Solvay Pharmaceuticals GmbH, Hanover, Germany.
